<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02878707</url>
  </required_header>
  <id_info>
    <org_study_id>201605056MIFA</org_study_id>
    <nct_id>NCT02878707</nct_id>
  </id_info>
  <brief_title>The Neuroprotective Effects of Dexmedetomidine During Brain Surgery</brief_title>
  <official_title>The Neuroprotective Effects of Dexmedetomidine During Brain Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexmedetomidine (DEX) is a Alpha-2 specific agonist, is a common ICU sedation medication. In
      brain tumor resection craniotomy, it is proven to be effective in improving postoperative
      hypertension and tachycardia, mitigates postoperative nausea and vomiting and relives
      postoperative pain. In addition, many animal experiments show that DEX inhibits the
      proapoptosis in the mitochondrial in vivo and therefore avoids neuronal injury. It is also
      reported to be neuroprotective to isoflurane-induced neurotoxicity and to improve cerebral
      focal ischemic region (penumbra). However, the neuroprotective effects were never
      investigated clinically in patients undergoing brain tumor resection surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2017</start_date>
  <completion_date type="Actual">April 14, 2020</completion_date>
  <primary_completion_date type="Actual">April 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with postoperative complications</measure>
    <time_frame>during postoperative period of hospital admission, approximately 10 days by estimation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum biomarkers changes</measure>
    <time_frame>Between preoperative baseline and postoperative day 1 to day 7.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Brain Tumor</condition>
  <condition>Cerebrovascular Disorders</condition>
  <arm_group>
    <arm_group_label>DEX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraoperative intravenous infusion of dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intraoperative intravenous infusion of 0.9% saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Intraoperative dexmedetomidine infusion</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>DEX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing elective craniotomy for supratentorial brain tumor resection or
             cerebral vascular surgery

          -  age between 20 to 80 yr

        Exclusion Criteria:

          -  Fever, elevated white blood cell or C-reactive protein

          -  Impaired liver function, eg. AST or ALT &gt;100; liver cirrhosis &gt; Child B class

          -  Impaired renal function, cGFR&lt; 60 ml/min/1.73 m2

          -  Cardiac dysfunction, such as heart failure &gt; NYHA class II
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chun-Yu Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anesthesiology Department, National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrovascular Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

